Full Press Release Details
Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE setmelanotide Marketing Authorization to include Children as Young as 2 Years Old.
RYTM
Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE setmelanotide Marketing Authorization to include Children as Young as 2 Years Old
Key Takeaway: Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE setmelanotide Marketing Authorization to include Children as Young as 2 Years Old